




**Figure 82: Liver HBV RNA in Mice Treated  
 with siNA Via HDI**




**Figure 83: Serum HBV DNA in Mice Treated with siNA Via HDI 5 and 7 days post treatment**




**Figure 84: Luciferase Dose Response  
 of select active siNA constructs**




**Figure 85: Luciferase Dose Response  
 of select active siNA constructs**




**Figure 86: Activity of Stab 7/8 Stabilized siNAs in HCV Replicon**




**Figure 87: Activity of Stabilized 7/8 siNAs Against HBV in HepG2 Cells**



**Figure 88: HBV/siNA to site 1580 Combination Constructs**




**Figure 89: HBV/siNA to site 1580 Combination Constructs**







**Figure 90: HBV/siNA to site 1580 Combination Constructs**



**Figure 91: PEI-Peg-Gal (3:1): Demonstration of Activity & Specificity HBV DNA**



**Figure 92: PEI-Peg-Gal (3:1): Demonstration of Activity & Specificity HBsAg**



**Figure 93: General Structure of PEI-PEG-TriGal with a lipid linker**

